Retinitis Pigmentosa Market Insights, Epidemiology and Market Forecast-2028
Retinitis Pigmentosa therapeutic market in the 7MM is driven at a CAGR of 28.90%. Standard-of-care (SOC) for the management of RP in the US primarily includes vitamins, lutein, docosohexanoic acid, calcium-channel blockers, and other options. Apart from the aforementioned SOCs, the recently and only approved therapy, Luxturna has been assessed to create a significant impact on Retinitis Pigmentosa market size.
View full press release